NeuroMab™ Anti-HRG Beta 1 Antibody (NRP-0422-P1897)

Figure 1 Points illustrating the results of flow cytometry analysis of the degree of binding of antibodies against human NRG1 protein (8a2, 8a4, 10bM3, and 10b2M3) to cell lines (NRG1-α/st293T or NRG1-) picture. b/st293T) stably expresses at a high level either of the human NRG1-α protein and the human NRG1-β1 protein with an HA tag added to its N-terminus.

Figure 2 is used to illustrate the analysis of antibodies by ELISA with partial-length human NRG1-α proteins (ag4a to ag13a and agPa) and partial-length human NRG1-β1 proteins (ag4b to ag13b, ag4b to ag13b, and Pb).

Figure 7 is a graph illustrating the results of analyzing the degree of binding of 8a4 and ch-8a4 to human NRG1-α protein by flow cytometry.

Figure 8 is a graph illustrating time-dependent changes in tumor volume in xenografted mice administered the antibody (8a4 or ch-8a4).

Figure 9 is a graph illustrating changes over time in the survival rate of xenografted mice administered with the antibodies (8a4, ch-8a4, 10b2M3, ch-10b2M3).

Figure 3 is a graph illustrating the results of analysis by flow cytometry of 8a2 and the antibodies (8a4, 10bM3, and 10b2M3) for inhibiting cleavage of human NRG1-α protein, which would otherwise be cleaved by PMA.

Figure 4 is a graph illustrating the results of analysis by flow cytometry of the activity of 8a2 and the antibodies (8a4, 10bM3 and 10b2M3) to inhibit human NRG1-β1 proteolysis, which would otherwise occur by PMA.

Figure 5 is a photograph illustrating the results of western blot analysis of human NRG1-α protein-induced ErbB3 phosphorylation inhibitory activity of 8a2 and the antibodies (8a4, 10bM3, 10b2M3).

Figure 6 is a dot diagram illustrating the results of flow cytometry analysis of the degree of binding of chimeric antibodies (ch-8a4, ch-10bM3, ch-10b2M3) to NRG1-α/st293T and NRG1-b. /st293T, or NRG1-b2/st293T.